Dectection of AMACR cancer markers in urine
AssigneeThe Regents of the University of Michigan
InventorsMark A. Rubin, Arul M. Chinnaiyan, Bharathi Laxman, Arun Sreekumar
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. The present invention also provides novel markers useful for the diagnosis, characterization, and treatment of prostate cancers. In particular, the present invention provides methods and compositions for the detection of α-methylacyl-CoA racemase (AMACR) in the urine as a marker for prostate cancer detection.
Claims8
A method of detecting the presence or absence of prostate cancer in a subject, comprising:
- a) providing
- i) urine from a subject;
- ii) a reagent for detecting α-methylacyl-CoA racemase in said urine;
- and
- b) contacting said urine with said reagent under conditions such that said reagent detects the presence or absence of α-methylacyl-CoA racemase in said urine;
- c) determining the presence or absence of prostate cancer in said subject based on said presence or absence of α-methylacyl-CoA racemase in said urine.
Dependencies are inferred from the claim text.